Tisch Cancer Institute at Mount Sinai


 

ASH 2024 Insights: Ph3 BOREAS Study - Navtemadlin vs. Best Available Therapy in JAK Inhibitor R/R MF

55 views
December 27, 2024
Comments 0
Login to view comments. Click here to Login